TVTX - Travere Therapeutics, Inc.
IEX Last Trade
17.34
0.100 0.577%
Share volume: 17,189
Last Updated: Fri 27 Dec 2024 08:30:32 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$17.24
0.10
0.58%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
3.67%
1 Month
-4.92%
3 Months
26.91%
6 Months
114.73%
1 Year
87.16%
2 Year
-9.93%
Key data
Stock price
$17.34
DAY RANGE
$17.10 - $17.72
52 WEEK RANGE
$5.50 - $20.33
52 WEEK CHANGE
$97.78
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Eric M. Dube
Region: US
Website: travere.com
Employees: 460
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: travere.com
Employees: 460
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Travere Therapeutics, Inc. focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the. treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy.
Recent news